Treatment outcomes and next-generation sequencing of a rare malignancy - urachal carcinoma: case report and literature review
Open Access
- 21 April 2026
- journal article
- case report
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1744925
Abstract
UrC is a rare malignancy with uncertain pathogenesis. The main symptoms include gross hematuria, abdominal pain, and an abdominal mass. The lack of comprehensive clinical analysis necessitates selecting an optimal therapeutic strategy for each patient. Here, we present a comprehensive review of the clinical manifestations, diagnosis, and treatment of UrC, illustrated with a case successfully managed through surgical intervention and adjuvant chemoradiotherapy. Meanwhile, the analysis of NGS detected two tumor-specific mutated genes: MYC (gene amplification, CN: 59.5) and FLT1 (missense mutation, c.1061G>A (p.R354Q), abundance: 2.1%). These findings may provide insights into tumor growth and guide therapeutic strategies.Keywords
This publication has 42 references indexed in Scilit:
- CACA guidelines for holistic integrative management of urothelial carcinomaHolistic Integrative Oncology, 2024
- Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumabIJU Case Reports, 2023
- Clinical sequencing identifies potential actionable alterations in a high rate of urachal and primary bladder adenocarcinomasCancer Medicine, 2023
- Urachal carcinoma: A novel staging system utilizing the National Cancer DatabaseCancer Medicine, 2022
- Current Understanding of Urachal Adenocarcinoma and Management StrategyCurrent Oncology Reports, 2020
- Urachal cancer—current concepts of a rare cancerDer Pathologe, 2019
- Targeting MYC in cancer therapy: RNA processing offers new opportunitiesBioEssays, 2016
- Urachal carcinoma: Clinicopathologic features and long‐term outcomes of an aggressive malignancyCancer, 2006
- Immunoglobulin superfamily proteins in Caenorhabditis elegans 1 1Edited by G. von HeijneJournal of Molecular Biology, 2000
- N-myc amplification causes down-modulation of MHC class I antigen expression in neuroblastomaCell, 1986